Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Effect of Fasting on Temporal Variation in the Nephrotoxicity of Amphotericin B in Rats

Michel LeBrun, Louis Grenier, Michel G. Bergeron, Louise Thibault, Gaston Labrecque, Denis Beauchamp
Michel LeBrun
Centre de Recherche en Infectiologie, Faculté de Médecine, 1 and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Grenier
Centre de Recherche en Infectiologie, Faculté de Médecine, 1 and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel G. Bergeron
Centre de Recherche en Infectiologie, Faculté de Médecine, 1 and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Thibault
School of Dietetics and Human Nutrition, Macdonald Campus of McGill University, Montréal, Québec, Canada H9X 3V9 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaston Labrecque
Centre de Recherche en Infectiologie, Faculté de Médecine, 1 and Faculté de Pharmacie, 3 Université Laval, Sainte-Foy, Québec, Canada G1V 4G2, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Beauchamp
Centre de Recherche en Infectiologie, Faculté de Médecine, 1 and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.3.520
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Evidence for temporal variation in the nephrotoxicity of amphotericin B was recently reported in experimental animals. The role of food in these variations was determined by studying the effect of a short fasting period on the temporal variation in the renal toxicity of amphotericin B. Twenty-eight normally fed and 28 fasted female Sprague-Dawley rats were used. Food was available ad libitum to the fed rats, while the fasted animals were fasted 12 h before and 24 h after amphotericin B injection to minimize stress for the animals. Water was available ad libitum to both groups of rats, which were maintained on a 14-h light, 10-h dark regimen (light on at 0600 h). Renal toxicity was determined by comparing the levels of excretion of renal enzyme and the serum creatinine and blood urea nitrogen (BUN) levels at the time of the maximal (0700 h) or the minimal (1900 h) nephrotoxicity after the intraperitoneal administration of a single dose of dextrose (5%; control group) or amphotericin B (50 mg/kg of body weight; treated group) to the rats. The nephrotoxicities obtained after amphotericin B administration at both times of day were compared to the nephrotoxicities observed for time-matched controls. In fed animals, the 24-h urinary excretion ofN-acetyl-β-d-glucosaminidase and β-galactosidase was significantly higher when amphotericin B was injected at 0700 and 1900 h. The excretion of these two enzymes was reduced significantly (P < 0.05) in fasting rats, and this effect was larger at 0700 h (P < 0.05) than at 1900 h. The serum creatinine level was also significantly higher (P < 0.05) in fed animals treated at 0700 h than in fed animals treated at 1900 h. Fasting reduced significantly (P < 0.05) the increase in the serum creatinine level, and this effect was larger in the animals treated at 0700 h. Similar data were obtained for BUN levels. Amphotericin B accumulation was significantly higher (P < 0.05) in the renal cortexes of fed rats than in those of fasted animals, but there was no difference according to the time of injection. These results demonstrated that fasting reduces the nephrotoxicity of amphotericin B and that food availability is of crucial importance in the temporal variation in the renal toxicity of amphotericin B in rats.

Amphotericin B is a polyene macrolide antifungal agent with a broad spectrum of activity. It remains the most effective agent for the treatment of serious systemic mycoses (11, 13, 23). The amphipathic property of the amphotericin B chemical structure facilitates its binding to sterols of the cell membrane, which induces disruption of the membrane’s integrity and cell death (4, 6). Although this antifungal agent binds preferentially to ergosterol (the sterol of the fungal cell wall), it also binds to cholesterol (the sterol of mammalian cell membranes) (6, 12, 28). Despite its high nephrotoxic potential and the recent introduction of newer antifungal agents, amphotericin B remains the drug of choice for the treatment of severe systemic fungal infections (10, 11, 13, 29).

The clinical use of amphotericin B is limited by a dose-dependent renal toxicity that is reported to be found in up to 80% of treated patients (13, 25). The clinical presentation of nephrotoxicity includes azotemia, renal tubular acidosis, impairment of the ability to concentrate urine, electrolyte abnormalities such as hypokalemia, and sodium and magnesium wasting. Several factors that modulate amphotericin B toxicity were described over the last few years, and different approaches to reducing the renal toxicity of this drug have recently been identified. Salt supplementation (18, 25) and encapsulation of amphotericin B into liposomes (19-21) were shown to reduce significantly the adverse effects of amphotericin B in patients.

Another approach that might contribute significantly to a reduction in the incidence of amphotericin B toxicity is the time of the day that the drug is given. In fact, a marked circadian stage dependence of murine survival time was observed following acute and chronic administration of amphotericin B (26). Furthermore, we showed that the renal toxicity of amphotericin B (10 mg/kg of body weight for 10 days) was higher when the drug was injected into rats at 0700 h than at any other time of day (17). Thus, the temporal variation in amphotericin B nephrotoxicity could be of clinical importance because this antifungal agent is usually given to humans as a once-daily injection (13).

The objective of the present study was to determine the effect of fasting on the temporal variation in the nephrotoxicity of amphotericin B. The renal toxicity of amphotericin B was thus investigated in fed and in fasted rats receiving a single injection of the antifungal agent at the beginning of their resting period (0700 h) or activity period (1900 h).

MATERIALS AND METHODS

Animals and treatment.Fifty-six female Sprague-Dawley rats (Charles River Breeding Laboratories Inc., Montréal, Québec, Canada) that weighed between 184 and 224 g and that were housed on a 14-h light, 10-h dark cycle (light on at 0600 h) were used in this study. A week after their arrival, the animals were divided into two groups of 28 rats each. The first group had free access to food (Rat Laboratory Chow pellets; Charles River Breeding Laboratories Inc.) and water throughout the entire experiment. The second group was fasted for 12 h before and 24 h after the injection of amphotericin B, but water was available ad libitum. The length of fasting was set up to minimize stress to the animals. The first group of rats (n = 7) received a single dose of amphotericin B (Fungizone; 50 mg/kg given intraperitoneally [i.p.]), whereas 5% dextrose (1 ml given i.p.) was given to the control animals. The injection time was 0700 or 1900 h because our previous study showed that this was the time of maximal (0700 h) and minimal (1900 h) amphotericin B nephrotoxicity (17). The single large dose of amphotericin B was used to be able to quantify renal toxicity by using early and sensitive markers of tubular damage (urinary enzymes) or late and less sensitive markers (creatinine and blood urea nitrogen [BUN] levels).

Animals were housed in individual metabolic cages throughout the experiment, and urine was collected under mineral oil to avoid evaporation. The urine of each animal was collected over two periods of 24 h (0 to 24 and 48 to 72 h after the injections). The urine was collected, its volume was noted, and it was centrifuged (1,430 ×g) for 15 min. The enzymatic activities of β-galactosidase (β-GAL) and N -acetyl-β-d-glucosaminidase (NAG) were measured in urine. The excretion of these enzymes in urine are early and sensitive markers of tubular damage.

Immediately before the injection of amphotericin B or dextrose, blood was collected from the retro-orbital plexus to measure lipid levels in plasma. The levels of cholesterol, high-density lipoproteins (HDLs), low-density lipoproteins (LDLs), and triglycerides (TGs) in the plasma of the fed and fasted rats were determined at the time of the single injection of amphotericin B since the renal toxicity of amphotericin B is influenced by serum lipid levels.

All animals were killed by decapitation 72 h after the injection of amphotericin B or dextrose. At the time of killing, blood was collected and centrifuged, and the serum was quickly frozen at −20°C to determine serum creatinine and BUN levels. These substances are late and less sensitive markers of renal toxicity. A midline abdominal incision was made, and both kidneys were removed and rapidly cut into two parts. The cortexes of both kidneys were dissected out, and a piece of tissue was immediately frozen in dry ice for determination of amphotericin B concentrations.

Biochemical analysis.The activities of β-GAL and NAG were determined by the method of Maruhn (22). The results are presented as the percent difference in enzyme activities between the treated and the time-matched control animals. The baseline levels of the activities of these enzymes in urine were also determined in fed and in fasted control rats. Renal function was evaluated by measuring serum creatinine and BUN levels in the blood collected at the time of killing. Serum creatinine and BUN levels were determined with a Hitachi 737 apparatus, and the results were presented as the percentage of the values measured in each time-matched control group. Cholesterol, HDL, and TG levels in plasma were measured with an RA 500 Tecknicon apparatus, and these results were expressed in millimoles per liter.

Amphotericin B assay.Samples of cortical tissue were homogenized in cold distilled water with a Tissue-Tearor RTM (Biospec Products, Bartlesville, Okla.) and were sonicated (Ultrasonic Processor W-375; Bionetics Ltd., Montréal, Québec, Canada). The intracortical accumulation of amphotericin B was determined by the modified microbiological assay of Bannatyne et al. (2). The test was performed in triplicate on antibiotic medium 12 (Difco Laboratories, Detroit, Mich.) with Paecilomyces varioti ATCC 22319 as the indicator organism. The plates were incubated at 37°C for 18 h. Standards (0.1 to 20 μg/ml) were prepared in blank cortex homogenized in cold distilled water. The lower limit of sensitivity of the microbiological assay was 0.53 μg/g of tissue.

Statistical analyses.Data are presented as means ± standard deviations. The statistical analyses were performed with the StatView SE + Graphics (1988) program (Abaccus Concepts Inc., Berkeley, Calif.). An analysis of variance by a least-squares method was used to determine the statistical differences between groups. If the F test indicated a difference within groups (P < 0.05), group comparisons were carried out with the Fisher’s protected least-significant-difference test, and a P value of <0.05 was considered statistically significant.

RESULTS

Urinary enzyme excretion.Figure1 presents the percent change in the level of excretion of NAG and β-GAL in urine collected from 0 to 24 h after a single injection of amphotericin B. Fed and fasted control animals showed similar baseline levels of the activities of these enzymes in urine. For the fed rats, the excretion of NAG was significantly higher (P < 0.05) in the urine of rats treated with amphotericin B at 0700 and 1900 h than in their time-matched controls. Figure 1A also shows a significant temporal variation in the toxicity of the drug: amphotericin B treatment increased the level of NAG excretion by 390% ± 60% at 0700 h and by 240% ± 90% at 1900 h (P < 0.05). Figure1A also shows that fasting reduced the level of excretion of NAG compared with that for the time-matched controls at both times of day and that this effect was more important at 0700 h than at 1900 h. Fasting abolished the time-dependent variations in NAG excretion. In urine collected from 48 to 72 h, the NAG activity was significantly higher in fed and fasted rats treated at 0700 h than in their time-matched controls and animals treated at 1900 h (P < 0.05) (data not shown). These data were predictable since fasted rats had free access to food 24 h after the single injection of amphotericin B or dextrose.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Twenty-four-hour urinary excretion of NAG (A) and β-GAL (B) (mean ± standard deviation percentage of the control level of excretion) 0 to 24 h after a single injection of amphotericin B (50 mg/kg) at 0700 or 1900 h in normally fed and fasted rats. §, significantly different from time-matched controls (P < 0.05); —∗—, statistical difference between groups under the extremity of the line (P < 0.05).

The level of excretion of β-GAL in urine measured from 0 to 24 h after amphotericin B injection is presented in Fig. 1B. Fed rats treated at 0700 and 1900 h had significantly higher levels of urinary excretion of β-GAL than their time-matched controls (P < 0.05), and this effect was greater when the antifungal agent was administered at 0700 h than when it was administered at 1900 h (P < 0.05). Figure 1B also illustrates the fact that fasting reduced the level of β-GAL excretion at both times of treatment but that the time-dependent variations in the nephrotoxicity persisted in these animals because the β-GAL activities measured at 0700 were still significantly higher (P < 0.05) than the activities found in the urine of rats injected at 1900 h. No significant difference in the level of excretion of β-GAL in urine collected from 48 to 72 h after amphotericin B administration was found (data not shown).

Renal function.The effect of amphotericin B on the BUN and serum creatinine levels in fed and fasted rats 72 h after the injection is presented in Fig. 2. In comparison to their time-matched controls, the BUN levels increased only when fed and fasted rats were treated at 0700 h (Fig. 2A). At 1900 h, injection of the antifungal agent did not induce any significant change in the BUN levels in either group of rats. Fasting reduced significantly (P < 0.05) the increase in BUN levels in animals treated at 0700 h. Figure 2B shows that injection of amphotericin B to fed rats at 0700 h produced serum creatinine levels that were significantly (P < 0.05) higher than those in the sera of their time-matched controls. A temporal variation was found in fed rats because the effect of the antifungal agent on the serum creatinine level was larger at 0700 h than at 1900 h. Fasting abolished the toxicity of the drug on the kidney because serum creatinine levels remained within the normal range; no time-dependent variations in serum creatinine levels were observed in these animals.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

BUN (A) and serum creatinine (B) levels (mean ± standard deviation percentage of the control levels) 72 h after a single injection of amphotericin B (50 mg/kg) at 0700 or 1900 h in normally fed and fasted rats. §, significantly different from time matched controls (P < 0.05); —∗—, statistical difference between groups under the extremity of the line (P < 0.05).

Intracortical concentration of amphotericin B.Figure3 presents the amphotericin B levels in the renal cortex 72 h after a single amphotericin B injection to fed and fasted rats at 0700 or 1900 h. Fasting reduced significantly (P < 0.05) the concentration of amphotericin B in the renal cortex at both times of the injection. Furthermore, no significant difference in the accumulation of the drug in the renal cortex in fed and fasted rats treated at 0700 or 1900 h was found.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Amphotericin B levels (mean ± standard deviation) in the renal cortex 72 h after a single injection of amphotericin B (50 mg/kg) at 0700 or 1900 h in normally fed and fasted rats. The values are expressed as micrograms per gram of tissue. —∗—, statistical difference between groups under the extremity of the line (P < 0.05).

TG, cholesterol, and HDL levels in plasma.Table1 presents the HDL, cholesterol, and TG levels in fed and fasted rat plasma taken a few minutes before amphotericin B injection. Fasting or time of day did not have any significant effect on serum HDL levels. However, the cholesterol levels of fasting rats were significantly (P < 0.05) lower at 1900 h than at 0700 h. Finally, fasting reduced significantly (P < 0.05) the plasma TG levels at both times of day.

View this table:
  • View inline
  • View popup
Table 1.

HDL, cholesterol, and TG levels in plasma of fed and fasted rats

DISCUSSION

The present study indicates the effects of a short fasting period on the temporal variations in the nephrotoxicity of amphotericin B. The excretion of NAG and β-GAL in urine and the serum creatinine and BUN levels were found to be significantly higher in fed animals treated at 0700 h than in fed animals treated at 1900 h. Temporal variations in enzyme excretion persisted in fasted rats, but fasting was associated with a lower level of toxicity of amphotericin B and a lower level of accumulation of amphotericin B in the renal cortex.

Temporal variations in the nephrotoxicity of amphotericin B have been reported previously (17, 26). In mice kept on a 12-h light, 12-h dark cycle, Skubitz et al. (26) showed that amphotericin B (35 mg/kg given i.p.) killed 25% of the mice treated early in the resting period (2 h after lights on) and 87% of the mice treated early in the activity span (2 h after lights off). We previously studied the nephrotoxicity of amphotericin B produced by chronic i.p. administration of 10 mg/kg for 10 days using determination of cellular regeneration, BUN and serum creatinine levels, and the level of accumulation of amphotericin B in the renal cortex (17). In agreement with the present data obtained for fed rats, our previous study indicates that the highest level of toxicity was obtained when amphotericin B was injected at 0700 h (i.e., at the beginning of the resting period) compared with that when amphotericin B was injected at some other time of day.

The mechanisms of the temporal variation in the nephrotoxicity of amphotericin B are still unknown. In agreement with our previous work (17), a first hypothesis could be that the highest level of toxicity of the antifungal agent observed at 0700 h is due to temporal changes in the level of accumulation of drug in the kidney and in its pharmacokinetics. Unfortunately, these data could not be reproduced in the present study. This discrepancy could be explained by methodological differences because the effect of chronic administration of the amphotericin B was studied in our previous work (17), while determination of the effect of fasting forced us to use a single acutely administered large dose in the present work. Could the time-dependent variations in the nephrotoxicity of amphotericin B be explained by temporal changes in the pharmacokinetics of the drug? To date, no data support this aspect of the hypothesis. However, the temporal changes in pharmacokinetics may not explain the data because amphotericin B has a long elimination half-life in human serum (15 days; only 3% of the total dose is excreted by the kidneys) (1) and in rats (16 to 18 h) (14). In addition, no data in the literature describe the effect of fasting on the pharmacokinetics of amphotericin B in serum and tissue. Thus, further studies are needed to confirm or refute this first working hypothesis.

Another possibility could be that the effect of diet on amphotericin B is due to an interaction between the antifungal agent and cholesterol, proteins, or lipoproteins in the blood (5, 9). Studies done with experimental animals suggested that the renal toxicity of amphotericin B is either increased when LDL-associated amphotericin B was given to hypercholesterolemic rabbits (15) or decreased in the presence of increased levels of TGs in serum (8, 27) or when the interaction between amphotericin B-LDL is inhibited (3). Studies done with humans suggested that low cholesterol levels in serum are associated with a lower level of renal toxicity of amphotericin B (7, 24) but that a higher incidence of toxicity was observed in patients with high serum LDL-cholesterol levels (30, 32). Experiments done in cell culture suggest that an increase in the level of association of amphotericin B with LDL enhanced the toxicity of amphotericin B to kidney cells (31,32) since the cellular uptake of amphotericin B seems to be mediated through the LDL receptors (16).

Our study shows significant differences in the renal toxicity of amphotericin B in fed animals injected at 0700 and 1900 h in the presence of similar levels of TGs and cholesterol in serum. However, these differences were significantly attenuated by fasting, which induced significantly lower levels of TGs in serum but similar levels of cholesterol. In other words, the protective effect of fasting seems to correlate with the low serum TG levels. By contrast, Chavanet et al. (8) found that serum TG levels correlated significantly with the 50% lethal dose of amphotericin B in mice. It is thus clear that the relationship between amphotericin B nephrotoxicity and the levels of TGs in serum as well as the levels of other serum components should be investigated further.

A last hypothesis could be that the susceptibility of the kidney to amphotericin B administration varied as a function of time of day because of temporal changes in the level of binding of amphotericin B with its receptor sites. Binding would be increased when the animals are eating, and this would explain why the toxicity was the greatest at the end of the activity period (i.e., at 0700 h). Fasting would reduce the level of binding to the receptor sites, and this would explain why the nephrotoxicity was least at the end of the resting period because rodents are not eating much in their sleeping period. Further research at the receptor level is needed to prove or disprove this working hypothesis.

ACKNOWLEDGMENTS

This study was supported by the Fonds pour la Formation de Chercheurs et l’Aide à la Recherche. M. LeBrun is the recipient of a studentship from the Fonds pour la Formation de Chercheurs et l’Aide à la Recherche.

FOOTNOTES

    • Received 11 June 1998.
    • Returned for modification 12 September 1998.
    • Accepted 20 December 1998.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. ↵
    1. Atkinson A. J. Jr.,
    2. Bennett J. E.
    (1978) Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13:271–276.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Bannatyne R. M.,
    2. Cheung R.,
    3. Devlin H. R.
    (1977) Microassay for amphotericin B. Antimicrob. Agents Chemother. 11:44–46.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Barwicz J.,
    2. Gareau R.,
    3. Audet A.,
    4. Morisset A.,
    5. Villiard J.,
    6. Gruda I.
    (1991) Inhibition of the interaction between lipoproteins and amphotericin B by some delivery system. Biochem. Biophys. Res. Commun. 181:722–728.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Bolard J.
    (1986) How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta 864:257–304.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Brajtburg J.,
    2. Elberg S.,
    3. Bolard J.,
    4. Kobayashi G. S.,
    5. Levy R. A.,
    6. Ostlund R. E. Jr.,
    7. Schlessinger D.,
    8. Medoff G.
    (1984) Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 149:986–997.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Brajtburg J.,
    2. Powderly W. G.,
    3. Kobayashi G. S.,
    4. Medoff G.
    (1990) Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:183–188.
    OpenUrlFREE Full Text
  7. ↵
    1. Chabot G. G.,
    2. Pazdur R.,
    3. Valeriote F. A.,
    4. Baker L. H.
    (1989) Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 78:307–310.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Chavanet P.,
    2. Joly V.,
    3. Rigaud D.,
    4. Bolard J.,
    5. Carbon C.,
    6. Yeni P.
    (1994) Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 38:963–968.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Cooper G. R.,
    2. Myers G. L.,
    3. Smith S. J.,
    4. Schlant R. C.
    (1992) Blood lipid measurements. Variations and practical utility. JAMA 267:1652–1660.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Drouhet E.,
    2. Dupont B.
    (1987) Evolution of antifungal agents: past, present, and future. Rev. Infect. Dis. 9:S4–S14.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Gallis H. A.,
    2. Drew R. H.,
    3. Pickard W. W.
    (1990) Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308–329.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Gruda I.,
    2. Nadeau P.,
    3. Brajtburg J.,
    4. Medoff G.
    (1980) Application of differential spectra in the ultraviolet-visible region to study the formation of amphotericin B-sterol complexes. Biochim. Biophys. Acta 602:260–268.
    OpenUrlPubMed
  13. ↵
    1. Khoo S. H.,
    2. Bond J.,
    3. Denning D. W.
    (1994) Administering amphotericin B—a practical approach. J. Antimicrob. Chemother. 33:203–213.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Kim H.,
    2. Loebenberg D.,
    3. Marco A.,
    4. Symchowicz S.,
    5. Lin C.
    (1984) Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob. Agents Chemother. 26:446–449.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Koldin M. H.,
    2. Kobayashi G. S.,
    3. Brajtburg J.,
    4. Medoff G.
    (1985) Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob. Agents Chemother. 28:144–145.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Krieger M.
    (1983) The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis. Anal. Biochem. 135:383–391.
    OpenUrlCrossRefPubMed
  17. ↵
    1. LeBrun M.,
    2. Grenier L.,
    3. Gourde P.,
    4. Bergeron M. G.,
    5. Labrecque G.,
    6. Beauchamp D.
    (1996) Nephrotoxicity of amphotericin B in rats: effects of the time of administration. Life Sci. 58:869–876.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Llanos A.,
    2. Cieza J.,
    3. Bernardo J.,
    4. Echevarria J.,
    5. Biaggioni I.,
    6. Sabra R.,
    7. Branch R. A.
    (1991) Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. 40:302–308.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Lopez-Berestein G.,
    2. Fainstein V.,
    3. Hopfer R.,
    4. Mehta K.,
    5. Sullivan M. P.,
    6. Keating M.,
    7. Rosenblum M. G.,
    8. Mehta R.,
    9. Luna M.,
    10. Hersh E. M.,
    11. Reuben J.,
    12. Juliano R. L.,
    13. Bodey G. P.
    (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J. Infect. Dis. 151:704–710.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Lopez-Berestein G.,
    2. Mehta R.,
    3. Hopfer R.,
    4. Mills K.,
    5. Kasi L.,
    6. Mehta K.,
    7. Fainstein V.,
    8. Luna M.,
    9. Hersh E. M.,
    10. Juliano R. L.
    (1983) Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infect. Dis. 147:939–945.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Lopez-Berestein G.,
    2. Rosenblum M. G.,
    3. Mehta R.
    (1984) Altered tissue distribution on amphotericin B by liposomal encapsulation. Cancer Drug Delivery 1:199–205.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Maruhn D.
    (1976) Rapid colorimetric assay of beta-galactosidase and N -acetyl-beta-glucosaminidase in human urine. Clin. Chim. Acta 73:453–461.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Meyer R. D.
    (1992) Current role of therapy with amphotericin B. Clin. Infect. Dis. 14:S154–S160.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Pontani D. R.,
    2. Sun D.,
    3. Brown J. W.,
    4. Shahied S. I.,
    5. Plescia O. J.,
    6. Schaffner C. P.,
    7. Lopez-Berestein G.,
    8. Sarin P. S.
    (1989) Inhibition of HIV replication by liposomal-amphotericin B. Antivir. Res. 13:119–125.
    OpenUrl
  25. ↵
    1. Sabra R.,
    2. Branch R. A.
    (1990) Amphotericin B nephrotoxicity. Drug Saf. 5:94–108.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Skubitz K. M.,
    2. Wick M.,
    3. Skubitz A.,
    4. Langevin T.,
    5. Olshefski R.,
    6. Von Roemeling R.,
    7. Sothern R.,
    8. Hrushesky W.
    (1986) Timing of amphotericin B therapy is a critical determinant of toxicity. Annu. Rev. Chronobiol. 3:183–186.
    OpenUrl
  27. ↵
    1. Souza L. C.,
    2. Maranhao R. C.,
    3. Schrier S.,
    4. Campa A.
    (1993) In vitro and in vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J. Antimicrob. Chemother. 32:123–132.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Vertut-Croquin A.,
    2. Bolard J.,
    3. Chabert M.,
    4. Gary-Bobo C.
    (1983) Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol or ergosterol containing phospholipid vesicles: a circular dichroism and permeability study. Biochemistry 22:2939–2944.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Warnock D. W.
    (1991) Amphotericin B: an introduction. J. Antimicrob. Chemother. 28:27–38.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Wasan K. M.,
    2. Conklin J. S.
    (1997) Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. 24:78–80.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Wasan K. M.,
    2. Rosenblum M. G.,
    3. Cheung L.,
    4. Lopez Berestein G.
    Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.Antimicrob. Agents Chemother.381994223227 (Erratum, 38:2230.)
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Wasan K. M.,
    2. Cassidy S. M.
    (1998) Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:411–424.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Effect of Fasting on Temporal Variation in the Nephrotoxicity of Amphotericin B in Rats
Michel LeBrun, Louis Grenier, Michel G. Bergeron, Louise Thibault, Gaston Labrecque, Denis Beauchamp
Antimicrobial Agents and Chemotherapy Mar 1999, 43 (3) 520-524; DOI: 10.1128/AAC.43.3.520

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Fasting on Temporal Variation in the Nephrotoxicity of Amphotericin B in Rats
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
Effect of Fasting on Temporal Variation in the Nephrotoxicity of Amphotericin B in Rats
Michel LeBrun, Louis Grenier, Michel G. Bergeron, Louise Thibault, Gaston Labrecque, Denis Beauchamp
Antimicrobial Agents and Chemotherapy Mar 1999, 43 (3) 520-524; DOI: 10.1128/AAC.43.3.520
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596